tilavonemab

01/01/2021 - "Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial."
01/01/2021 - "We assessed the safety and efficacy of tilavonemab for the treatment of progressive supranuclear palsy. "
01/01/2021 - "Participants (aged ≥40 years) diagnosed with possible or probable progressive supranuclear palsy who were symptomatic for less than 5 years, had a reliable study partner, and were able to walk five steps with minimal assistance, were randomly assigned (1:1:1) by interactive response technology to tilavonemab 2000 mg, tilavonemab 4000 mg, or matching placebo administered intravenously on days 1, 15, and 29, then every 28 days through to the end of the 52-week treatment period. "
01/01/2017 - "The double-blind, placebo-controlled phase 1 study tested single doses of ABBV-8E12 ranging from 2.5 to 50 mg/kg in 30 patients with progressive supranuclear palsy (PSP). "
10/01/2021 - "Neuropathology of progressive supranuclear palsy after treatment with tilavonemab - Author's reply."

01/01/2023 - "Tilavonemab was generally well tolerated but did not demonstrate efficacy in treating patients with early Alzheimer's disease. "
01/01/2017 - "Based on the acceptable safety and tolerability profile of single doses of ABBV-8E12, AbbVie is currently enrolling patients into two phase 2 clinical trials to assess efficacy and safety of multiple doses of ABBV-8E12 in patients with early Alzheimer's disease or PSP."
01/01/2023 - "Further investigations of tilavonemab in early Alzheimer's disease are not warranted."
01/01/2023 - "Tilavonemab in early Alzheimer's disease: results from a phase 2, randomized, double-blind study."
01/01/2017 - "Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies."

08/01/2023 - "The individual had been enrolled in a phase 2 trial and received a monoclonal tau antibody (tilavonemab, ABBV-8E12); he died of intrahepatic cholangiocarcinoma and gastrointestinal bleeding during the clinical trial. "

08/01/2023 - "The individual had been enrolled in a phase 2 trial and received a monoclonal tau antibody (tilavonemab, ABBV-8E12); he died of intrahepatic cholangiocarcinoma and gastrointestinal bleeding during the clinical trial. "

01/01/2017 - "Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies."
01/01/2023 - "Two other anti-tau monoclonal antibodies have been discontinued for the treatment of primary tauopathies, i.e., gosuranemab and tilavonemab. "